...
首页> 外文期刊>Breast care >Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy
【24h】

Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy

机译:男性乳腺癌:手术和遗传特征和多学科管理策略

获取原文

摘要

Background: Male breast cancer (MBC) is a rare disease with a rising incidence trend. The major risk factors related to MBC are a positive family history of breast cancer (BC) and BRCA1/2 mutations, which indicate a relevant genetic role. Methods: In this retrospective series, we enrolled 69 male patients presenting with male breast cancer (MBC) between 01/01/1992 and 31/12/2018, and 26 high-risk not-affected men presenting between 01/01/2016 and 31/12/2018. Participants’ electronic clinical records were reviewed. Patients’ data reported age at diagnosis, tumor characteristics, therapeutic management, and BRCA1/2 status as well as a family history of breast, ovarian, or prostate cancer (PCa) in first-degree relatives. Results: We analyzed 69 MBC patients. Median age was 64 years. The majority of tumors diagnosed were of an early TNM stage. The most frequent histological subtype was invasive ductal carcinoma (76.7%). Hormone receptors were positive in >90% of MBC cases. Nearly all patients underwent modified radical mastectomy or total mastectomy. Adjuvant endocrine therapy was delivered in 59.4%. Among MBC-affected patients, we recorded a high percentage of a positive family history of BC. Mutational analysis for the BRCA1/2 genes was performed in 17 MBC patients; 11.8% were carriers of BRCA2 pathogenic mutations. Among 26 healthy high-risk subjects included in this case series, 4 were BRCA1 mutation carriers and 9 were BRCA2 mutation carriers. Discussion: We evaluated the distribution of clinicopathological characteristics in MBC subjects and assessed the frequency of mutations in the BRCA genes in affected patients and healthy high-risk subjects, with the aim of proposing a surveillance program for BC and PCa.
机译:背景:雄性乳腺癌(MBC)是一种罕见的疾病,发病率升高。与MBC相关的主要风险因素是乳腺癌(BC)和BRCA1 / 2突变的阳性家族史,表明相关的遗传作用。方法:在此回顾性系列中,我们注册了69例患有男性乳腺癌(MBC)的男性患者(MBC)01/01/19/192和12月31日在01/01/2016之间的高危非受影响的男性。 31/12/2018。综述了参与者的电子临床记录。患者的数据报告在诊断,肿瘤特征,治疗管理和BRCA1 / 2的年龄以及一级亲属的乳腺癌,卵巢或前列腺癌(PCA)的家族史。结果:我们分析了69名MBC患者。中位年龄为64岁。诊断出的大多数肿瘤是早期的TNM阶段。最常见的组织学亚型是侵入性导管癌(76.7%)。激素受体呈阳性> 90%的MBC病例。几乎所有患者都经过改良的根治性乳房切除或全乳房切除术。佐剂内分泌治疗以59.4%递送。在影响MBC影响的患者中,我们录得高比例为BC的积极家族史。 BRCA1 / 2基因的突变分析在17名MBC患者中进行; 11.8%是BRCA2致病性突变的载体。在这种情况下包含的26个健康的高风险受试者中,4是BRCA1突变载体,9是BRCA2突变载体。讨论:我们评估了MBC受试者临床病理特征的分布,并评估了受影响患者和健康高风险主体的BRCA基因突变的频率,目的是提出BC和PCA的监督程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号